Compare e l f Beauty Inc (ELF) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

ELF Beauty trades at $108.16, down 1.62% today, with strong technical momentum indicated by bullish moving averages. The company demonstrates robust revenue growth, reaching $1.31B in 2025, though net margins compressed to 3.38% in 2026. Recent expansion includes rhode brand launches in Europe via Sephora and innovative marketing campaigns like the 'Mirror Mix' music album. Analyst consensus shows mixed sentiment with 48% buy ratings but a $95.91 price target below current levels.

ELF's premium valuation (P/E 110.34) reflects growth expectations but poses risk if execution falters. International expansion and brand innovation provide upside, while high debt levels and margin pressure present challenges. The stock's technical strength contrasts with fundamental valuation concerns, requiring careful monitoring of earnings delivery against elevated expectations.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.